Description: Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Home Page: tevogen.com
15 Independence Boulevard
Warren,
NJ
07059
United States
Phone:
877-838-6436
Officers
| Name | Title |
|---|---|
| Dr. Ryan H. Saadi M.D., M.P.H, M.P.H. | Co-Founder, CEO & Chairman |
| Mr. Kirti Desai CPA | Chief Financial Officer |
| Dr. Neal Flomenberg M.D. | Chief Scientific Officer and Global R&D Lead |
| Mr. Stephen Chen M.B.A. | Chief Technical Officer |
| Mr. Mittul Mehta | Chief Information Officer & Head of Tevogen.ai |
| Mr. Tapan V. Shah | Head of Investor Relations & Corporate Development |
| Mr. Sadiq Khan M.B.A. | Chief Commercial Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 2.8857 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2024-02-15 |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |